Optimum effectiveness of intestinal alpha-glucosidase inhibitors: importance of uniform distribution through a meal
- PMID: 3883743
- DOI: 10.1093/ajcn/41.3.511
Optimum effectiveness of intestinal alpha-glucosidase inhibitors: importance of uniform distribution through a meal
Abstract
A major barrier to the widespread clinical use of an alpha-glucosidase inhibitor such as Acarbose, is the unpleasant gastrointestinal symptoms of carbohydrate malabsorption associated with its use. Acarbose is usually administered as a tablet and eaten with the first mouthful of the meal, making its uniform distribution through the meal unlikely. In the present study, Acarbose was crushed to a powder and mixed through a test meal before it was consumed. Six healthy young men consumed test meals containing 75 g carbohydrate either as whole brown rice or as ground brown rice. When Acarbose was uniformly mixed through a ground rice meal prior to digestion it produced dose-dependent reductions in the postprandial glucose, insulin and GIP responses which were evident at doses as low as 12.5 mg. The responses to whole brown rice were intermediate between those to 12.5 and 25 mg Acarbose in ground brown rice. In tablet form Acarbose was only one quarter as effective in flattening the post prandial glucose and insulin responses as it was in powder form. These results highlight the importance of uniform distribution of Acarbose through a carbohydrate meal in order to achieve maximum effectiveness in delaying digestion and absorption and yet not promoting carbohydrate malabsorption.
Similar articles
-
Scope and specificity of acarbose in slowing carbohydrate absorption in man.Diabetes. 1981 Nov;30(11):951-4. doi: 10.2337/diab.30.11.951. Diabetes. 1981. PMID: 7028548
-
Acute and short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man.Dig Dis Sci. 1987 Feb;32(2):139-44. doi: 10.1007/BF01297101. Dig Dis Sci. 1987. PMID: 3542445 Clinical Trial.
-
The effects of an alpha-glucoside hydrolase inhibitor on glycemia and the absorption of sucrose in man determined using a tracer method.Diabetes. 1984 Mar;33(3):207-13. doi: 10.2337/diab.33.3.207. Diabetes. 1984. PMID: 6365657
-
A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.Drug Saf. 1994 Dec;11(6):432-44. doi: 10.2165/00002018-199411060-00005. Drug Saf. 1994. PMID: 7727053 Review.
-
Pharmacology of alpha-glucosidase inhibition.Eur J Clin Invest. 1994 Aug;24 Suppl 3:3-10. Eur J Clin Invest. 1994. PMID: 8001624 Review.
Cited by
-
Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.Drugs. 1988 Mar;35(3):214-43. doi: 10.2165/00003495-198835030-00003. Drugs. 1988. PMID: 3286212 Review.
-
Targeting glucose metabolism for healthy aging.Nutr Healthy Aging. 2016 Oct 27;4(1):31-46. doi: 10.3233/NHA-160007. Nutr Healthy Aging. 2016. PMID: 28035340 Free PMC article. Review.
-
The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer.Cancers (Basel). 2020 Oct 6;12(10):2872. doi: 10.3390/cancers12102872. Cancers (Basel). 2020. PMID: 33036247 Free PMC article.
-
Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis.Nutr Diabetes. 2021 Mar 3;11(1):11. doi: 10.1038/s41387-021-00152-5. Nutr Diabetes. 2021. PMID: 33658478 Free PMC article.
-
Effect of acarbose on carbohydrate tolerance during administration of a fibre-free formula diet on healthy subjects.Eur J Clin Pharmacol. 1986;30(5):607-14. doi: 10.1007/BF00542422. Eur J Clin Pharmacol. 1986. PMID: 3019703
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical